Interspecies prediction of pharmacokinetics and tissue distribution of doxorubicin by physiologically‐based pharmacokinetic modeling
- 28 April 2020
- journal article
- research article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 41 (4-5) , 192-205
Abstract
The aim of the study was to develop a physiologically‐based pharmacokinetic (PBPK) model to describe and predict whole‐body disposition of doxorubicin following intravenous administration. The PBPK model was established using previously published data in mice and included 10 tissue compartments: lungs, heart, brain, muscle, kidneys, pancreas, intestine, liver, spleen, adipose tissue, and plasma. Individual tissues were described by either perfusion‐limited or permeability‐limited models. All parameters were simultaneously estimated and the final model was able to describe murine data with good precision. The model was used for predicting doxorubicin disposition in rats, rabbits, dogs, and humans using interspecies scaling approaches and was qualified using plasma and tissue observed data. Reasonable prediction of the plasma pharmacokinetics and tissue distribution was achieved across all species. In conclusion, the PBPK model developed based on a rich dataset obtained from mice, was able to reasonably predict the disposition of doxorubicin in other preclinical species and humans. Applicability of the model for special populations, such as patients with hepatic impairment, was also demonstrated. The proposed model will be a valuable tool for optimization of exposure profiles of doxorubicin in human patients.Keywords
Funding Information
- Celgene
This publication has 72 references indexed in Scilit:
- The limited intestinal absorption via paracellular pathway is responsible for the low oral bioavailability of doxorubicinXenobiotica, 2012
- A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systemsNanomedicine: Nanotechnology, Biology and Medicine, 2012
- Physiologically Based Pharmacokinetic Model of Amphotericin B Disposition in Rats Following Administration of Deoxycholate Formulation (Fungizone®): Pooled Analysis of Published DataThe AAPS Journal, 2011
- Population Pharmacokinetics and Pharmacodynamics of Doxorubicin and Cyclophosphamide in Breast Cancer PatientsClinical Pharmacokinetics, 2007
- Evaluation of the effects of dietary n-3 fatty acid supplementation on the pharmacokinetics of doxorubicin in dogs with lymphomaAmerican Journal of Veterinary Research, 2006
- Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer DrugsClinical Pharmacokinetics, 2002
- Physiological Parameter Values for Physiologically Based Pharmacokinetic ModelsToxicology and Industrial Health, 1997
- Pharmacokinetics and toxicity of intraarterial Adriamycin for hepatocellular carcinoma: Effect of coadministration of lipiodolJournal of Hepatology, 1991
- Clinical and pharmacokinetic study of 96-h infusions of doxorubicin in advanced cancer patientsEuropean Journal of Cancer and Clinical Oncology, 1989
- Clinical Pharmacokinetics of DoxorubicinClinical Pharmacokinetics, 1988